FULC — Fulcrum Therapeutics Inc · catalysts, narrative & risks

Overview

As of the October 30, 2026 close, Fulcrum Therapeutics (NASDAQ: FULC) trades around $3.71 with a market capitalization near $283M, and the company is in the middle of a defining corporate transition: exiting its lead clinical program (pociredir) and pivoting into an all-stock merger with Slate Medicines to become a migraine-focused biotechnology business [2][9]. The stock has been intensely news-driven.

Recent catalysts (last ~1–3 months, as of 2026-10-31)